Compare AFBI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | BDSX |
|---|---|---|
| Founded | 1928 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 122.0M |
| IPO Year | 2020 | 2020 |
| Metric | AFBI | BDSX |
|---|---|---|
| Price | $22.39 | $12.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 32.9K | ★ 58.9K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.42 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.70 |
| P/E Ratio | $17.34 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $17.75 | $0.25 |
| 52 Week High | $22.47 | $20.21 |
| Indicator | AFBI | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 72.89 | 35.65 |
| Support Level | $19.84 | $6.00 |
| Resistance Level | N/A | $12.70 |
| Average True Range (ATR) | 0.20 | 1.07 |
| MACD | 0.18 | -0.38 |
| Stochastic Oscillator | 97.75 | 1.22 |
Affinity Bancshares Inc is a bank holding company. The bank provides a range of financial services, including checking and savings accounts, certificates of deposit, mortgage, commercial and consumer loans, and money transfer services, operating across parts of Georgia and offering specialized lending such as dental practice and indirect automobile loans across the Southeastern United States. Its business mainly involves accepting public deposits and investing them in real estate and commercial loans, as well as mortgage-backed securities. The company also gathers deposits nationwide through its virtual bank, FitnessBank, and uses additional funding sources such as Federal Home Loan Bank borrowings.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.